Program

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada and accredited by the Canadian Association for the Study of the Liver.

Participants can claim up to a maximum of 14.5 study credits.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found on the conference website.

Your certificate of attendance will be issued following completion of the post-conference survey.

Monday, October 6, 2025
8:00 AM																Masterclass Session I Gideon Hirschfield & Or Steg Saban Gideon Hirschfield, The Autoimmune and Rare Liver Disease Programme, Toronto General Hospital Or Steg Saban, The hospital for sick children
10:00 AM																Morning Break
10:30 AM																Masterclass Session II *Orlee Guttman* Orlee Guttman, British Columbia Children's Hospital
12:00 PM																Lunch Break
12:15 PM																Industry Symposium Sponsored Symposia Program
1:30 PM																STC Session I - Genetic cholestasis The biologic mechanisms and pathophysiology of cholestasis - Andréanne Zizzo Adult presentations of "pediatric" genetic cholestatic diseases - Silvia Vilarinho Ductal plate malformations and ciliopathies: a primer for all! - *Jessica Wen* New and emerging therapies in cholestatic liver disease - *Richard Thompson* Round Table & Q&A Andreanne Zizzo, Western University, Children's Hospital, LHSC Silvia Vilarinho, Yale University Jessica Wen, The Children's Hospital of Philadelphia Richard Thompson, King's College London
3:30 PM																Afternoon Break
4:00 PM																STC Session II - Autoimmune Liver Disease Primer on primary biliary cholangitis: biology and presentation - *Hin Hin Ko* New therapies for primary biliary cholangitis - *Gideon Hirschfield* Primary sclerosing cholangitis: where do we stand in the adult world - *Kristel Leung* Recurrence of autoimmune liver disease post transplant - Rahima Bhanji Autoimmune hepatitis : what treatment gaps remain? - Aldo Montano Loza Q&A Hin Hin Ko, UBC Gideon Hirschfield, The Autoimmune and Rare Liver Disease Programme, Toronto General Hospital Kristel Leung, Queen’s University Rahima Bhanji, University of Alberta Aldo Montano_Loza, University of Alberta
6:00 PM																Reception
Tuesday, October 7, 2025
7:00 AM																Industry Symposium Sponsored Symposia Program
8:00 AM																STC Session III - Controversies in treatment for rare liver disease "Overlap" syndromes: Is it time for adult physicians to believe pediatric pediatric conditions - Nanda Kerkar Steroid minimization in childhood autoimmune liver disease - Or Steg Saban Microbiome manipulation and GI-Liver disease - *Richard Kellermayer* Treatment and management options in intrahepatic cholestasis of pregnancy - *Saumya Jayakumar* Transition of hepatology patients from pediatric to adult care - *Susan Gilmour* Q&A Nanda Kerkar, Massachusetts General Brighaml for Children Or Steg Saban, The hospital for sick children Richard Kellermayer, Baylor College of Medicine Saumya Jayakumar, University of Alberta Susan Gilmour, University of Alberta
10:00 AM																Morning Break
10:30 AM																STC Session IV - Pot-pourri Cystic fibrosis liver disease in the era of Trikafta - *Michael Narkewicz* Alpha-1 antitrypsin deficiency: will molecular therapy change outcomes? - Jean-Phillipe Wallach Hepatitis Delta: entering a new era - *Carla Coffin* IgG4 disease: a case-based discussion on treatments now and emerging - Gideon Hirschfield & Natassia Tan Vascular Disorders of the Liver: The Role of Interventional Radiology - Manraj Heran Q&A Michael Narkewicz, Children's Hospital Colorado and University of Colorado School of Medicine Jean-Philippe Wallach, University of British Columbia Carla Coffin, University of Calgary Natassia Tan, University Health Network Manraj Heran, The University of British Columbia
12:30 PM																Break
1:00 PM																Joint CASL & CST Liver Forum Opening Remarks Liver Forum Session 1 - MELD and MELD Alternatives The Case for Change: Where MELD Fails Alternative Models for Organ Allocation: International and Canadian Perspectives Panel Discussion Q&A Liver Forum Session 2 - Immunosuppression in Liver Transplantation To Induce or Not to Induce: Evolving Practices in 2025 Maintenance Strategies: Balancing Efficacy and Toxicity Diagnosis and Management of Antibody-Mediated Rejection in Liver Transplantation Panel Discussion Q&A Liver Forum Session 3 - Expanding the Donor Pool NRP in DCD: The Canadian Experience and Ethical Frameworks Ex-vivo Liver Perfusion: Clinical Experience and Research Priorities How Should Canada Adopt and Scale These Technologies? - Panel Discussion